Affymax, Inc. (NASDAQ:AFFY)
| CAPS Rating |
|
|---|---|
| Open | $10.82 |
| Previous Close | $10.53 |
| Daily Range | $10.43 - $10.83 |
| 52-Week Range | $3.93 - $11.13 |
| Market Cap | $372.25M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 943,624 |
| Average Daily Volume | 0 |
How do you think AFFY will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AFFY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AFFY News and Commentary
- 5 of Last Week's Biggest Winners – The Motley Fool
- Trading Plan for January 18, 2012 – Blog at The Motley Fool
- 3 High Flyer Trade Setups – Blog at The Motley Fool
- Stocks on the Road to Greatness – The Motley Fool
- Another Entry in the Genome Patent Rumble – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Takeda Opts Not To Market Affymax's Anemia Drug In Japan – SmartMoney
- 5 of Last Week's Biggest Winners – The Motley Fool
- Whoa! What Just Happened to My Stock? – The Motley Fool
- A Soaring Biotech With Room to Run – The Motley Fool
- US Stocks Tumble Into the Close As European Summit Opens; DJIA Loses 199 – SmartMoney
- Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug – The Motley Fool
- US Stocks Decline After ECB Disappoints, Summit Spurs Debt Jitters – SmartMoney
- Affymax's Stock Soars on Hope for Anemia Drug Approval – Minyanville
- Company News for December 6, 2011 - Corporate Summary – NASDAQ
- Up 20%, but Uncertainty Still Looms – The Motley Fool
- Mid-Day Update: Stocks Sitting Higher as Europe Hope Rises; ISM Services Index Falls – NASDAQ
- Affymax, Takeda Anemia Drug Faces FDA Panel Review – SmartMoney
- Options Market Picks: 9 Highly Liquid Stocks with Bullish Options Sentiment – NASDAQ

RSS Headlines
Fool UK